[Multi-agent combination chemotherapy for adult acute lymphoblastic leukemia--individualized chemotherapy].
Eighteen adults with acute lymphoblastic leukemia (ALL) including 14 previously untreated and 4 relapsed cases were treated with individualized and intensified induction and post-remission therapy. CNS prophylaxis was performed with i. th. methotrexate alone and started early during induction. All patients achieved complete remission. In a median follow up of 65 weeks, 2 yr-disease free survival (DFS) rate was 73.5 +/- 13.0% in previously untreated patients. This treatment program has resulted in markedly improved remission rate and DFS in adults with ALL.
Uzuka
Y
Y
Third Dept. of Internal Medicine, Tohoku University School of Medicine.
Saito
Y
Y
Takahashi
H
H
Komatsu
M
M
Ito
T
T
Toyota
T
T
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D015996:Survival Rate; D014751:Vindesine / Q000008:administration & dosage
D003561:Cytarabine; D005047:Etoposide; D003520:Cyclophosphamide; D011239:Prednisolone; C015019:enocitabine; D008942:Mitoxantrone; D014751:Vindesine